Announcements Trials
Browse Landscape

Status

Completed 2Terminated 1

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hereditary Cancer 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Diagnostic Tests, Routine × Clear all
NCT05645133 2023-06-15

QPlus Pediatric Reference Interval

HemoSonics LLC

Terminated
93 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03067389 2019-01-15

Combined Breast Cancer Risk Study

Myriad Genetic Laboratories, Inc.

Completed
553 enrolled

Hereditary Cancer

NCT03081455 2017-08-08

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Myriad Genetic Laboratories, Inc.

Completed
145 enrolled

Hereditary Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡